Navigation Links
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo

Demonstrates Positive Effect on Objective and Subjective Sleep Measures

MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- According to study results presented today at SLEEP 2007, the 21st annual meeting of the Associated Professional Sleep Societies (APSS), VEC-162, a balanced melatonin (MT1/MT2) receptor agonist being developed by Vanda Pharmaceuticals Inc. , demonstrated improvements in objective and subjective measures of sleep onset and maintenance in a Phase III trial of transient insomnia.

VEC-162 was assessed in a randomized, double-blind, placebo-controlled, multi-center clinical trial that enrolled 412 adults in a sleep laboratory setting using a phase-advance, first-night assessment model of transient insomnia. The trial examined VEC-162 dosed 30 minutes before bedtime at 20, 50 and 100 mg versus placebo.

"Study patients reported they were falling asleep faster and staying asleep longer," said Tom Roth, Ph.D., Director of the Henry Ford Sleep Disorders and Research Center in Detroit, MI, presenter at today's APSS session. "These subjective measures support data collected in the sleep lab and provide an important dimension for assessing the efficacy of VEC-162."

VEC-162 demonstrated statistically significant improvements at all three tested doses compared to placebo (p<0.001) in the primary endpoint of the trial, Latency to Persistent Sleep (LPS), a measure of sleep onset. VEC-162 also produced statistically significant improvements relative to placebo in Latency to Non-Awake (LNA), another measure of sleep onset, Wake After Sleep Onset (WASO), a measure of sleep maintenance, and Total Sleep Time (TST). VEC-162 was also demonstrated to be safe and well tolerated.

VEC-162 also demonstrated improvements relative to placebo on subjective sleep measures. For LPS, all VEC-162 doses showed a trend toward improvement and 50 mg (p<0.001) and 100 mg (p=0.018) achieved statistical
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ... Symphony® CGM System as a non-invasive, wireless continuous ... F. Doman , Executive Chairman and Interim CEO ... Financial Capital Markets, Tenth Annual Equity Conference. ... presentation to prospective corporate partners and investors at ...
(Date:1/15/2014)... , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ... Summary,Although the past decade has seen ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... , , LONDON , Jan. 28 ... Frost & Sullivan presents Japan Stent Technology with the 2009 European ... advancing localized drug delivery in the coronary care segment. The company ... device care that is witnessing a merging of device and pharmaceutical ...
... , ST. LOUIS , Jan. 27 ... received Section 510 (k) clearance from the U.S. Food and ... first ophthalmic device linking patients and doctors between eye exams ... a frequent but brief exam on their ForeseeHome AMD Monitor, ...
Cached Medicine Technology:Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design 2Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design 3Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design 4Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design 5Notal Vision's ForeseeHome(TM) AMD Monitor Receives FDA Clearance 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... immune system could work in humans , MONDAY, March 15 ... viable treatment for people suffering from severe asthma, researchers say. ... early edition of the Proceedings of the National Academy ... organ transplantation, where multipotent stem cells in the form of ...
... ... (GWEDC ) recently launched LocationScout, GWEDC’s cutting edge site search engine. ... geared specifically towards businesses, site selection professionals and other end users. ... website positions GWEDC as one of the nation’s leaders among economic ...
... , Salt Lake City , and Denver in May are set to help employers improve hearing conservation efforts and prevent noise-induced hearing loss among their workers. , ... , ... ... ...
... March 15 Duffy & Duffy, a preeminent medical malpractice law firm based in Uniondale, N.Y. , ...  Mary Rita and Frank bring more than 50 years of combined experience in medical malpractice and general liability.  They will ... ... , , ...
... The film "Avatar" isn,t the only 3-D blockbuster making a ... unveiled a new technique for growing 3-D cell cultures, a ... millions of dollars in drug-testing costs. The research is reported ... easy enough for most labs to set up immediately. It ...
... 15 UniCare Health Plan of West Virginia , Inc. ... the baby pantry at the Dream Center, which is part of the ... during the Love the Little Ones Nursery Drive . The ... March 15 at the Dream Center and will conclude on ...
Cached Medicine News:Health News:Stem Cells Might One Day Treat Severe Asthma 2Health News:Greater Wichita EDC Launches New Custom Designed GIS Database 2Health News:Greater Wichita EDC Launches New Custom Designed GIS Database 3Health News:Greater Wichita EDC Launches New Custom Designed GIS Database 4Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 2Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 3Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 4Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 5Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 6Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 7Health News:Duffy & Duffy Continues Steady Growth with Addition of Two Seasoned Medical Malpractice Attorneys 2Health News:Duffy & Duffy Continues Steady Growth with Addition of Two Seasoned Medical Malpractice Attorneys 3Health News:Duffy & Duffy Continues Steady Growth with Addition of Two Seasoned Medical Malpractice Attorneys 4Health News:3-D cell culture: Making cells feel right at home 2Health News:3-D cell culture: Making cells feel right at home 3Health News:UniCare, Power Country 105.9 Hold Nursery Drive for the Beckley Dream Center 2Health News:UniCare, Power Country 105.9 Hold Nursery Drive for the Beckley Dream Center 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: